NeurologyLive ®

John Didsbury, PhD: Phase IIa Trial of T3D-959 in Mild to Moderate Alzheimer Disease

Study results suggest that agonist stimulation of PPAR delta may be an effective therapeutic strategy to addressing dysfunctional metabolism in Alzheimer disease.

By: John Didsbury, PhD

Published: August 11, 2018

“That's what this drug is doing, it's getting you back on your game. It's refeeding the brain that is being starved in Alzheimer."

John Didsbury, PhD, Founder and CEO of T3D Therapeutics, Inc., sat with NeurologyLive to speak to the final results of the phase IIa exploratory and feasibility clinical trial of T3D-959 in patients with mild-to-moderate Alzheimer disease. The results were presented by Didsbury at the 2018 Alzheimer’s Association International Conference in Chicago, Illinois.

T3D-959, a dual peroxisome proliferator activated receptor (PPAR) delta/gamma agonist with 15-fold higher PPAR delta potency, was studied in 36 patients with mild-to-moderate Alzheimer disease. Subjects were randomized to 1 of 4 doses of T3D-959 daily for 14 days—3 mg, 10 mg, 30 mg, or 90 mg—assessed for safety and tolerability, and evaluated for changes from baseline in cerebral metabolic rate of glucose (FDG-PET imaging), functional connectivity of the hippocampus (BOLD-fMRI) and cognitive function (ADAS-Cog11 and DSST).

The results show multiple signals of efficacy, Didsbury notes, from changes in the metabolome, changes in glucose metabolism in the brain, and improvements in cognitive testing. FDG-PET results demonstrated changes in brain glucose uptake in a dose-dependent fashion and may increase relative glucose uptake in needed regions of the brain. The cognitive evaluation by ADAS-Cog11 demonstrated that all ApoE4-negative patients improved 4.8–6.1 points at low and mid (3 mg–30 mg) doses, while ApoE3-positive patients improved 1–3.5 points at mid and high (30 mg–90 mg) doses. DSST results revealed an average improvement of 2.4 points in subjects with moderate Alzheimer and 7 points in subjects with mild Alzheimer regardless of the dose or genotype.

Didsbury adds that T3D-959 is essentially treating Alzheimer disease as a chronic anorexia of the brain because the brain is not receiving the energy needed—a result of insulin resistance.

After the completion of the phase IIa trial, a phase IIb will be underway where subjects with mild-to-moderate Alzheimer disease will be dosed with T3D-959 for 6 months. Researchers will assess cognitive performance and look at glucose metabolism in the brain using FDG-PET brain scans.

Related Content

James Hendrix, PhD: First Practice Guidelines for Clinical Evaluation of Alzheimer Disease Released

These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.

Alzheimer's Association Develops First Practice Guidelines for Clinical Evaluation of Alzheimer Disease, Other Dementias

The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.

Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

Clive Ballard, MD: Pimavanserin In Patients With Dementia-Related Psychosis

Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.

Krista Lanctot, PhD: Nabilone Significantly Improves Agitation in Alzheimer Disease

The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.

Jeff D. Williamson, MD, MHS: SPRINT-MIND Trial Preliminary Results

The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.

Lynn Kramer, MD: BAN2401 Phase IIb Clinical Study Results

This is the first large late-stage clinical trial to further support the amyloid hypothesis.

BAN2401 Slows Cognitive Decline in Alzheimer Disease

BAN2401 produced a dose-dependent substantial reduction in brain amyloid plaque at the highest dose, resulting in subjects converting to amyloid negative.

Anton P. Porsteinsson, MD: Addressing Trial Design and Symptom Intervention in Alzheimer Disease

The director of the University of Rochester Alzheimer's Disease Care, Research and Education Program spoke about the need to rethink trial design and Alzheimer neuropsychiatric symptom management.

Harald Hampel, MD, PhD, MA, MSc: Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study

ANAVEX 2-73 is being studied as the first potential precision medicine biomarker-guided, targeted therapeutic in Alzheimer disease.

Ian Maidment, PhD: The ZED Study Findings in Alzheimer Disease

The senior lecturer in Clinical Pharmacy at Aston University spoke about the findings of the ZED study, which looked into the use of hypnotic z-drugs.

Nir Lipsman, MD, PhD: MR-Guided Focused Ultrasound to Open Blood-Brain Barrier in Alzheimer Disease

This technology offers a non-invasive, image-guided and reversible approach to blood-brain barrier, suggesting the possibility of its use in Alzheimer disease.

Clive Ballard on Pimavanserin for Treatment of Hallucinations, Delusions Associated with Dementia-Related Psychosis

The professor of age-related diseases and Dean of the University of Exeter Medical School provided insight into the safety and efficacy of pimavanserin studied in treatment for Alzheimer psychosis.

Dennis Selkoe, MD: Crenezumab Significantly Reduces Aβ Oligomers in CSF

The results conclude that treatment with crenezumab was associated with a consistent decrease in Aβ oligomer levels in the CSF.

Ian Maidment, PhD: Treating Sleep Problems in Those with Dementia

The senior lecturer in Clinical Pharmacy at Aston University talked about issues facing the medical community in treating those with dementia who have sleep problems.

Geoff Kerchner, MD, PhD: Gantenerumab as Disease-Modifying Treatment in Early Alzheimer Disease

Higher doses of gantenerumab, a monoclonal antibody designed to bind to aggregated Aβ and remove beta plaques, will be investigated in phase III trials.

Davangere Devanand, MBBS, MD: Lithium for Agitation in Alzheimer Disease

The professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.

Harald Hampel, MD, PhD, MA, MSc: Phase IIa Study of ANAVEX 2-73 in Treatment of Alzheimer Disease

The phase IIb/III study is scheduled to initiate enrollment of approximately 450 patients, randomized 1:1:1 to 2 different ANAVEX 2-73 doses or placebo.

Samantha Budd Haeberlien, PhD: Progress in Alzheimer Drug Development

Haeberlein spoke about a number of topics in the Alzheimer space, including the progress that has been made and her excitement for the future.

John Didsbury, PhD: Phase IIa Trial of T3D-959 in Mild to Moderate Alzheimer Disease

Study results suggest that agonist stimulation of PPAR delta may be an effective therapeutic strategy to addressing dysfunctional metabolism in Alzheimer disease.

*First Name*Last Name*Email*Verify Email:*Password*Verify Password*Country*State*Sub-specialty*Degree

Sign Up for Emails to get the Latest Breaking News, Exclusive Event Invites and More